文献速递其他结缔组织病

系统性硬化症患者外周血与皮肤中CD4+ T细胞及细胞因子水平变化及IL-35对CD4+ T细胞生长的作用

Altered CD4+ T cell and cytokine levels in peripheral blood and skin samples from systemic sclerosis patients and IL-35 in CD4+ T cell growth.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究纳入41例系统性硬化症患者和39例健康对照,检测外周血与皮肤活检中CD4+ T淋巴细胞及IL-35相关因子,并将CD4+ T细胞与皮肤成纤维细胞共培养。结果发现患者Th1/Th2降低、Th17/Treg升高,IL-35与IL-17A升高而IFN-γ、IL-10、TGF-β降低;重组IL-35可抑制增殖并上调IL-10、下调IL-17A、α-SMA和COL-1。

要点

  • 系统性硬化症患者外周血Th1/Th2降低、Th17/Treg升高,IL-35与IL-17A升高。
  • 患者皮肤组织IL-17A、FoxP3、TGF-β1、COL-1 mRNA及p-STAT1、p-STAT4升高。
  • 重组IL-35抑制CD4+ T细胞增殖并上调IL-10、下调IL-17A、α-SMA和COL-1。

核心结论

  • IL-35在系统性硬化症中抑制CD4+ T淋巴细胞增殖,但通过STAT1信号激活诱导Treg细胞分化,并影响皮肤成纤维细胞增殖与胶原表达。

研究设计与样本

  • 收集41例系统性硬化症患者和39例健康对照的外周血与皮肤活检,评估CD4+ T淋巴细胞及IL-35相关因子。
  • 将CD4+ T淋巴细胞与皮肤成纤维细胞共培养,并加入重组人IL-35和IL-35单克隆抗体评估细胞活力与活化。

主要发现

  • 患者外周血Th1/Th2比例低于对照、Th17/Treg比例高于对照(P < 0.05)。
  • 患者外周血IL-35和IL-17A水平高于对照,IFN-γ、IL-10和TGF-β水平低于对照。
  • 患者皮肤组织IL-17A、FoxP3、TGF-β1和COL-1 mRNA及p-STAT1、p-STAT4高于对照(P < 0.05)。
  • 患者CD4+ T+HSF细胞培养上清IL-6水平更高、IL-10水平更低,α-SMA、COL-1蛋白及Ki67阳性率更高。
  • 重组人IL-35处理抑制增殖(P < 0.001),增加IL-10并减少IL-17A、α-SMA和COL-1分泌;IL-35单抗可阻断上述效应(P < 0.05)。

临床怎么用

  • IL-35可能作为调控CD4+ T细胞增殖与Treg分化、影响成纤维细胞活化的潜在靶点,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study explored the role of IL-35 in CD4+ T lymphocyte and human skin fibroblast (HSF) activity and cytokine levels in systemic sclerosis. METHODS: Blood and skin biopsies were collected from 41 patients and 39 healthy controls to assess CD4+ T lymphocytes and IL-35-related factors. CD4+ T lymphocytes were co-cultured with HSFs, recombinant human IL-35 and IL-35 mAb to evaluate the cell viability, activation of CD4+ T lymphocytes and HSF cells. RESULTS: The proportion of blood Th1/Th2 was lower and Th17/Treg was higher in patients than in controls (P < 0.05). IL-35 and IL-17A levels were higher and IFN-γ, IL-10 and TGF-β levels were lower in patients than in controls. IL-17A, forkhead box P3, TGF-β1 and collagen type I (COL-1) mRNA and phospho (p)-signal transducer and activator of transcription (STAT) 1 and p-STAT4 were higher in skin tissues from patients than in those from controls (P < 0.05). IL-6 levels were higher, whereas IL-10 levels were lower in cell culture supernatants. α-Smooth muscle actin (α-SMA) and COL-1 proteins and Ki67 positivity were higher in CD4+ T + HSF cells from patients than in those from controls. Recombinant human IL-35 treatment inhibited proliferation (P < 0.001), but increased IL-10 and decreased IL-17A, α-SMA and COL-1 secretion into the conditioned medium of CD4+ T lymphocytes + HSFs from patients compared with those from controls. IL-35 mAb blocked the effects of IL-35 in CD4+ T + HSF cells (P < 0.05). CONCLUSIONS: IL-35 plays an inhibitory role in CD4+ T lymphocyte proliferation but induces Treg cell differentiation by STAT1 signalling activation, HSF proliferation and collagen expression in systemic sclerosis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yang C, Lei L, Pan J, et al. Altered CD4+ T cell and cytokine levels in peripheral blood and skin samples from systemic sclerosis patients and IL-35 in CD4+ T cell growth. Rheumatology (Oxford). 2022. PMID: 33878182. doi:10.1093/rheumatology/keab359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。